Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline ...

Positive dose-finding results with ACT-132577 - asset to progress to Phase 3 development in resistant hypertension Positive safety study with cenerimod - asset to progress into larger Phase 2 development in systemic lupus erythematosus Investor webcast to discuss Idorsia's strategy and pipeline today at 15:00 hrs ALLSCHWIL/BASEL, SWITZERLAND - 22 May 2017 - Actelion Ltd (SIX: ATLN) today provides an update on the progress being made to bring Idorsia Ltd to the SIX Swiss Exchange. Following the successful tender offer by Johnson & Johnson for Actelion, the approval of the Actelion shareholders to demerge the drug discovery and early clinical pipeline business, and progress with the anti-trust...